Cocrystal Pharma, Inc. (NASDAQ:COCP) Sees Large Decline in Short Interest

Cocrystal Pharma, Inc. (NASDAQ:COCP) saw a significant decrease in short interest in the month of September. As of September 30th, there was short interest totaling 175,246 shares, a decrease of 45.7% from the September 15th total of 322,748 shares. Approximately 1.5% of the company’s stock are sold short. Based on an average daily volume of 54,337 shares, the short-interest ratio is currently 3.2 days.

Analyst Ratings Changes

A number of research firms have issued reports on COCP. Weiss Ratings downgraded Cocrystal Pharma from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday, August 21st. HC Wainwright reissued a “buy” rating on shares of Cocrystal Pharma in a research report on Friday, October 9th. One analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Hold”.

Cocrystal Pharma Stock Up 1.9%

Shares of COCP stock traded up $0.02 during trading hours on Friday, hitting $1.05. 7,667 shares of the company’s stock traded hands, compared to its average volume of 808,197. The stock’s fifty day simple moving average is $1.13 and its two-hundred day simple moving average is $1.14. Cocrystal Pharma has a 12-month low of $0.76 and a 12-month high of $2.03. The stock has a market cap of $20.22 million, a price-to-earnings ratio of -1.38 and a beta of 1.48.

Cocrystal Pharma (NASDAQ:COCP) last posted its quarterly earnings results on Thursday, August 13th. The company reported ($0.23) earnings per share for the quarter, missing the consensus estimate of ($0.17) by ($0.06). The company had revenue of $0.11 million during the quarter, compared to the consensus estimate of $0.10 million. On average, equities analysts forecast that Cocrystal Pharma will post -0.69 earnings per share for the current fiscal year.

About Cocrystal Pharma

Cocrystal Pharma, Inc is a clinical-stage biotechnology company focused on discovering and developing antiviral therapies. The company uses a structure-based drug discovery platform to identify small-molecule compounds designed to interfere with essential viral replication proteins.

Its research programs have targeted a range of viral diseases, including influenza A, norovirus and coronaviruses. Cocrystal’s development activities have included orally administered antiviral candidates intended for the treatment or prevention of viral infections, with programs advancing through a combination of preclinical research and clinical development.

Founded in 2007 and formerly known as BioZone Pharmaceuticals, the company adopted the Cocrystal Pharma name after combining with Cocrystal Discovery in 2015.